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The molecular classification of melanoma and the advent of new drugs are changing the paradigm of
therapy for advanced melanoma. A review of the recent key studies was performed, followed by
a discussion in an expert forum. The aim of this review was to generate a therapeutic algorithm for
stage IV melanoma. Tumor genotyping for BRAF and/or KIT should be performed before selection
of therapy. For most BRAF-mutated melanoma patients and particularly those with a high tumor
load, vemurafenib or other BRAF inhibitors such as dabrafenib are the treatment of choice. KIT
inhibitors can be effective in KIT-mutant tumors, especially in those patients with mutations at exons
11 and 13. Ipilimumab is a good option for patients with nontargetable or nondetected mutations
and those who progress under therapy with vemurafenib or a KIT inhibitor. There is still a role for
conventional chemotherapy either as first-line treatment in BRAF wild-type patients or as salvage
therapy in second or third line, or after other treatment modalities. Participation in clinical trials is
strongly encouraged, either in first or in subsequent lines. New therapeutic options for advanced
melanoma are guided by tumor genotyping. The current therapeutic algorithm includes kinase
inhibitors, anti-CTLA4 therapy, immunotherapy, and chemotherapy, depending on the tumor geno-
type and response to previous treatments. Participation in clinical trials should always be encour-
aged because the treatment goal is long-term survival and potential cure in a subset of patients.
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INTRODUCTION
The management of metastatic melanoma has yielded
disappointing results until recent times. Some patients
obtained a benefit from regional treatments, but the
majority of them required systemic therapy that was
largely ineffective. Options included immunotherapy in
selected centers (and for selected patients), clinical trials
with new drugs, and, most commonly, chemotherapy.
Both new knowledge of the molecular biology of
melanoma and the advent of ipilimumab and specific
kinase inhibitors have dramatically changed this land-
scape. Melanoma is no longer envisioned as one single
tumor but a constellation of diseases having specific
molecular features. This new understanding allowed
the development of BRAF inhibitors, for instance, and
will likely foster the identification of other effective
and specific drugs. As new compounds enter clinical
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trials and eventually become widely available, deci-
sion trees will be required to use them correctly.
This review summarizes evidence that may help in
making clinical decisions and proposes an algorithm to
use systemic treatments. A review of the recent key
studies was performed, followed by a discussion in
an expert forum. Local therapies will continue to play
an important role in the management of regional dis-
ease but will not be covered in this review.
OPTIONS AND OUTCOME BEFORE
THE ERA OF NEW DRUGS
The prognosis of patients with stage IV melanoma has
remained unchanged for decades. A retrospective anal-
ysis published in 1983 showed a 1-year survival rate of
40% for stage IVA and 11% for stage IVC disease.1 In
2000, the Eastern Cooperative Oncology Group reported
a median overall survival of 8–10 months in patients
with soft tissue or lung metastases and 6 months in those
with visceral dissemination.2 Numerous efforts to
improve this outcome with the use of combined chemo-
therapy and immunotherapy proved to be unsuccessful.
A systematic review of 41 randomized clinical trials re-
vealed that combination regimens produced higher
response rates, but at the cost of increased toxicity and
with no benefit in overall survival.3 These trials had used
single-agent chemotherapy, combination chemotherapy,
interleukin-2 with or without interferon or combinations
of chemotherapy, and immunotherapy. In view of the
limited success of complex schemes, single-agent therapy
with dacarbazine, which achieves responses in 7%–15%
of patients, was accepted as a reasonable standard of
care in many institutions. Temozolomide and fotemus-
tine were also used because they had similar activity and
a favorable toxicity profile, and by crossing the blood–
brain barrier, they have activity in brain-metastasized
patients as well.4–6
Some types of immunotherapy stand out as excep-
tions to these poor results. Interleukin-2 yields com-
plete remissions in 6% of patients, most of which are
long-term survivors.7 Because of the side effects in
selected patients associated with this drug, it is usually
restricted to young patients with excellent perfor-
mance status and no comorbid conditions. Therapy
with interleukin-2 is offered in selected centers with
experience in the management of toxicity.
Adoptive cell therapy consists of the infusion of the
patient’s own tumor infiltrating lymphocytes after ex
vivo expansion or antigen-specific T lymphocytes, that
is, T-cell clones. The infusion is usually preceded by an
immune-depleting regimen including chemotherapy or
total-body irradiation. The procedure should be restricted
to highly selected patients and requires a technology that
is not widely available. In experienced hands, 3-year sur-
vival rates of up to 42% have been reported.8,9
ANTI-CTLA4 THERAPY
Ipilimumab is a fully humanized monoclonal antibody
directed to CTLA4. Long-term survival in some patients
was observed in phase 2 studies, although overall
response rates were low.10 A double-blinded phase 3
study in second line compared ipilimumab (3 mg/kg
every 3 weeks) versus ipilimumab plus a gp100 vaccine
versus the vaccine alone. Overall survival favored the
ipilimumab arms, with 45.6% and 23.5% of the patients
remaining alive at 1 and 2 years, respectively.11 Another
phase 3 study in first line compared dacarbazine versus
dacarbazine plus ipilimumab (10 mg/kg every 3 weeks).
Again, survival rates were superior in the ipilimumab
arm: 47% versus 36%, 28% versus 18%, and 20% versus
12% at 1, 2, and 3 years, respectively.12 Median overall
survival was 11 months for the ipilimumab plus dacar-
bazine combination versus 9 months for dacarbazine
alone. Although ipilimumab showed little benefit in
overall response rate or progression-free survival, a sur-
vival plateau appeared after 2 years of follow-up, with
20% of the patients remaining alive in the long term.
Based on these results, ipilimumab 3 mg/kg has been
approved by the Food and Drug Administration (FDA)
for first and second line, whereas the European Medicine
Agency (EMA) and the Therapeutic Goods Administra-
tion in Australia approved it for second-line therapy.
Interestingly, long-term benefit with ipilimumab does
not seem to depend on the BRAF status.13
Ipilimumab was the first agent to demonstrate a sig-
nificant overall survival benefit in metastatic melanoma
but generated new issues. Standard criteria for the eval-
uation of response are not accurate for patients treated
with ipilimumab, because initial lymphocyte infiltration
in the tumor may increase tumor size or lead to the
appearance of new lesions in computed tomography
images (pseudoprogression). As a consequence,
immune-related response criteria have been devel-
oped.14 Furthermore, ipilimumab is associated with
a new toxicity profile of immune-related side effects,
mostly cutaneous and gastrointestinal, which requiring
specific education and training of treating clinicians.
Future studies with the drug may be directed to the
identification of predictive factors and the combination
of ipilimumab with other drugs, such as BRAF inhib-
itors. Other agents that enhance the activity of the
immune system are under development, such as those
targeting PD1 and PD1 ligand. In the multicenter
phase 1 trial, anti-PD1 ligand antibody was given
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intravenously to a total of 207 patients as of February
2012. These included 55 with melanoma. Nine mela-
noma patients (of 52 who could be evaluated) showed
an objective response, either complete or partial.
Responses were durable in many patients, providing
evidence that this line of therapy should be part of
melanoma treatment in the future.15,16
SPECIFIC THERAPY IN BRAF-
MUTATED MELANOMA
Approximately 40% of melanomas present mutations
in BRAF, usually V600E and less commonly V600K
and others.17,18 This has allowed the development of
specific kinase inhibitors. A diagram showing the role
of BRAF in melanoma is given in Figure 1.19
BRAF inhibitors
Vemurafenib is a selective BRAF inhibitor that targets
the V600 mutant forms of the BRAF.20,21 Detection of
the BRAF mutation can be done in paraffin-embedded
specimens. The drug is active only in tumors harbor-
ing this kind of mutation, which needs to be detected
before treatment initiation. Whenever possible, the
mutation should be detected in metastatic tissue, as
disparities have been reported between primary and
metastatic lesions in some cases.22
A phase 2 study of vemurafenib in second/third line
showed objective responses in 53% of the patients and
a median progression-free survival of 6.7 months.23 The
median overall survival was 15.9 months. The most
common grade 3 adverse events requiring dose reduc-
tion were arthralgia, rash, UV A–dependent photosen-
sitivity, fatigue, and elevated transaminases in 2%–5%
of the patients.23,24 Skin lesions such as squamous cell
carcinoma and keratoacanthoma developed in 24% of
the patients and were managed by surgical excision.
A subsequent phase 3 trial compared vemurafenib—
960 mg every 12 hours—to dacarbazine in first line.25
The first interim analysis showed a response rate of
48% for vemurafenib (vs. 5% for dacarbazine) and
a median progression-free survival of 5 months (vs.
1.6). Based on these results, the FDA and the EMA
have approved vemurafenib for the treatment of
BRAF-mutated metastatic melanoma.
Vemurafenib is being investigated in a phase 1/2
study in combination with ipilimumab for advanced
disease. There are also ongoing studies in patients with
poor performance status or with brain metastases.26–28
Other BRAF inhibitors are being developed. Of these,
dabrafenib (GSK118436) obtained results similar to those
of vemurafenib in a phase 1/2 study.29 A recent compar-
ison of dabrafenib and dacarbazine in the BREAK-3 trial
showed that dabrafenib demonstrated significant
improvement in progression-free survival and overall
relapse rate compared with dacarbazine.30 Dabrafenib
also showed significant activity in brain metastases with
an overall response rate of 39% as first-line treatment and
31% in those who had previous brain radiotherapy.31
MEK inhibitors
MEK is a downstream target of the BRAF pathway,
which is depicted in Figure 1. MEK mutation has been
described as a possible mechanism of resistance to
BRAF inhibitors.32 Patients developing resistance to
BRAF inhibitors frequently show reactivation of the
MAPK pathway,33 and a specific MEK inhibitor, tra-
metinib (GSK1120212), has shown activity in patients
who were progressing with a BRAF inhibitor.34 A
recent phase 3 study, the METRIC trial, compared tra-
metinib versus chemotherapy with either dacarbazine
or paclitaxel in patients with BRAF-mutant nonresect-
able melanomas. The results showed that trametinib
conferred significant improvement in progression-free
survival and overall survival compared with either
chemotherapeutic modality.35
Combinations of specific inhibitors
Considerable effort is being dedicated to study the
resistance to BRAF inhibitors and a number of mech-
anisms have been proposed. For instance, preclinical
FIGURE 1. The BRAF-MEK pathway. Inappropriate acti-
vation of growth factor receptors (eg, KIT) or mutations
of the BRAF gene can lead to constant activation of MEK
1 or 2, with resultant effects on cells: increased prolifer-
ation, survival, and propensity for invasion. The diagram
is adapted from Meier et al.19
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models indicate the importance of MEK dependency in
BRAF-mutant melanoma and suggest that a combina-
tion of BRAF and MEK inhibitors could prevent the
emergence of resistance.36 A phase 1/2 study of the
BRAF inhibitor dabrafenib and the MEK inhibitor tra-
metinib has shown encouraging activity with lower
than expected toxicity. Among the 77 melanoma
patients treated with this therapy combination, the
overall response rate was 56% and the overall PFS
was 7.4 months. The authors concluded that the com-
bination had an acceptable safety profile along with
antitumor efficacy.37 Phase 3 trials comparing the
MEK/BRAF inhibitor combination to BRAF inhibitor
alone are currently underway.
Other mechanisms of resistance, independent of the
BRAF or MEK pathways, have been described and
point to new possible drug combinations.38–42 At this
time, the best strategy to prevent or overcome resis-
tance to BRAF inhibitors remains unknown and will be
the aim of future clinical trials. Given the heterogeneity
of melanoma, it is unlikely that one particular combi-
nation will work in all cases.
KIT inhibitors
Approximately 15% of mucosal (with an especially high
mutation rate in vulvovaginal melanomas43) and 23%
of acral melanomas have a mutation or amplification in
KIT,44 which could allow therapy with specific inhibi-
tors. A phase 2 trial of imatinib 800 mg/d in Chinese
patients reported a partial response rate of 23% and
stabilization in 30% of patients.45 There is a clear hier-
archy of mutations according to the response to tar-
geted drugs with some mutations being completely
resistant.46 Most imatinib-sensitive mutations in mela-
noma are found in exons 11 and 13. In a phase 2 study
from 28 patients with KIT mutation or amplification, 6
responded to the drug.46 All of them had tumors with
L576P or K642E mutations, the most common KIT mu-
tations in melanoma. Experience in Western patients is
more limited.46 Likewise, the incidence of KIT mutation
could differ depending on ethnicity. Ongoing studies
(NCT01395121) have been launched for another specific
inhibitor, nilotinib, in this population.
CONVENTIONAL CHEMOTHERAPY
AND OTHER COMPOUNDS
Twenty percent of melanomas harbor mutations in
N-RAS, whereas uveal melanomas typically have muta-
tions in GNAQ or GNA11, and other melanomas yet
show a variety of other mutations (PI3K pathway, MITF,
CDKs, etc.).47 MEK inhibitors, such as MEK162, could
play a role in some of these less common subgroups of
melanoma. This selective inhibitor of MEK1 and
MEK2 showed clinical efficacy with good tolerability
in an open-label phase 2 trial, among patients bearing
BRAF- and NRAS-mutated melanoma.47 Further
basic research and multi-institutional cooperation
will be critical in the future management of these
subgroups.
However, chemotherapy has traditionally been
associated with poor overall results, but some patients
clearly benefit from this approach. For this reason,
chemotherapy will still have a place as rescue strategy
in second or third line and in patients with nonmu-
tated melanoma.
A THERAPEUTIC ALGORITHM
As therapy for advanced melanoma becomes more
complex, it is important to delineate treatment algo-
rithms. Registration labels and drug availability will
drive the sequence. At this time, ipilimumab and
vemurafenib have been approved by regulatory agen-
cies, although cost constraints may limit access in some
countries. Other new drugs and combination options
mentioned above remain experimental.
Considering the high response rate associated with
vemurafenib, tumor genotyping is the first logical step
in the algorithm (Figure 2). BRAF mutation should be
searched for in all patients with metastatic mela-
noma.48 An automated polymerase chain reaction–
based diagnostic test has been developed and is
approved by the FDA.49 This test is very sensitive to
detect V600E mutations but is less sensitive for non-
V600E mutations. For this reason, if a mutation in
BRAF is not found, ordering a second analysis by an
alternative method could be justified. Acral and muco-
sal melanomas should also be tested for mutations in
BRAF and KIT. NRAS mutational status should be
determine in wilde-type BRAF melanoma, as MEK
inhibitors are now under clinical evaluation in
NRAS-mutated disease.47
Vemurafenib—and probably dabrafenib—is the pre-
ferred option in patients with BRAF-mutated mela-
noma. However, ipilimumab could be considered in
low-risk patients, that is, those with low tumor burden
and excellent performance status. Some of these
patients could become long-term survivors, whereas
the remaining would receive vemurafenib on progres-
sion with ipilimumab. As ipilimumab requires time to
produce an effective response, patients with short life
expectancy could be better served with other options.
Imatinib or another KIT inhibitor is indicated if a KIT
mutation is detected, although evidence in this regard is
less consistent than in the case of vemurafenib for
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BRAF-mutant melanoma. Ongoing studies will deter-
mine which KIT mutations are most amenable to treat-
ment with this kind of inhibitors.
Patients progressing on vemurafenib or a KIT inhib-
itor could receive ipilimumab or chemotherapy, de-
pending on performance status and drug availability.
Ipilimumab should also be considered as first-line ther-
apy whenever a targetable mutation is not detected in
the tumor. Immunotherapy with interleukin-2 or adop-
tive cell therapy should be restricted to selected patients
in centers with experience in these treatment modalities.
The importance of clinical trials cannot be overem-
phasized. The possibility to refer patients for clinical
investigation should be considered at any stage of the
patient’s evolution. The algorithm will be subjected to
changes as new alternatives demonstrate efficacy for
specific subgroups. For instance, MEK inhibitors or the
combination of BRAF and MEK inhibitors might be
considered in first-line for BRAF-mutated melanomas.
In the future, specific drugs could be developed to
treat melanoma with other mutations, in which the
detection of these mutations should become the stan-
dard of practice. Likewise, if markers predicting
response to ipilimumab or anti-PD1 antibodies are
finally found, they should be incorporated to the path-
ological workup.16
CONCLUSIONS
In 2012, therapy for advanced melanoma is determined
by the mutational status of the tumor. Vemurafenib is
the most active agent in BRAF-mutant melanoma,
whereas a KIT inhibitor could be considered in tumors
with a mutation in KIT. Ipilimumab should be
FIGURE 2. A therapeutic algorithm for advanced melanoma. Tumor molecular genotyping determines the options in
first-line treatment. Kinase inhibitors are the therapy of choice if a specific mutation is detected, although data are more
consistent for vemurafenib in BRAF-mutant melanoma than for KIT inhibitors in KIT-mutant tumors. Ipilimumab,
chemotherapy, or immunotherapy can be considered in nonmutated melanoma as first line or in mutated melanoma
after progression with specific drugs. It is very rarely possible to use ipilimumab after progression on BRAF inhibitors;
the use of these drugs in the first line cannot be excluded.
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considered as first-line for patients with no target muta-
tions or as second line in any patient. Chemotherapy may
have a role as salvage therapy in second or third line.
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